{"id":4327,"date":"2024-12-12T10:49:40","date_gmt":"2024-12-12T09:49:40","guid":{"rendered":"https:\/\/www.bayoosoft.com\/?p=4327"},"modified":"2025-08-13T15:57:29","modified_gmt":"2025-08-13T13:57:29","slug":"regulation-as-a-brake-on-innovation-how-the-mdr-delays-the-market-entry-of-medical-devices-and-what-companies-can-do-about-it","status":"publish","type":"post","link":"https:\/\/www.bayoosoft.com\/en\/bayoosoft-themis-en\/regulation-as-a-brake-on-innovation-how-the-mdr-delays-the-market-entry-of-medical-devices-and-what-companies-can-do-about-it\/","title":{"rendered":"Regulation as a brake on innovation? How the MDR delays the market entry of medical devices and what companies can do about it"},"content":{"rendered":"

Regulation as a brake on innovation? How the MDR delays the market entry of medical devices and what companies can do about it<\/h1><\/h1><\/div>

Regulation and special requirements for manufacturing and quality assurance are extremely important, especially in medical technology – after all, human lives depend on it. However, there are repeated discussions that criticize the fact that MDR and IVDR tend to hinder innovation and represent an enormous barrier to market entry. In this blog post, we address these critical voices and explain how companies can deal with MDR and IVDR.
<\/span><\/p>\n<\/div><\/div><\/div>

What are MDR and IVDR?<\/h2><\/h2><\/div>

The MDR (Medical Device Regulation) and the IVDR (In Vitro Diagnostic Regulation) are European regulations that govern the approval and monitoring of medical devices and in vitro diagnostics (IVD). They were introduced to ensure a higher level of protection for patients and users, increase transparency and improve product safety in the EU. The MDR came into force on May 26, 2021, and the IVDR on May 26, 2022. Both regulations replace previous EU directives. <\/p>\n<\/div><\/div><\/div>

What are the criticisms of the MDR and IVDR?<\/h2><\/h2><\/div>
<\/i><\/div>
What are the criticisms of the MDR and IVDR?<\/div><\/div>
<\/div>
The requirements for documentation, clinical studies and follow-up have increased considerably. This leads to higher costs for manufacturers, especially for small and medium-sized enterprises (SMEs) and start-ups. Many of these companies are finding it difficult to raise the increased financial and human resources, which can lead to them withdrawing from the market or not entering it at all. <\/div><\/div><\/div>
<\/i><\/div>
Bottlenecks at notified bodies<\/div><\/div>
<\/div>
The number of notified bodies that are allowed to certify under the new regulations has fallen significantly, leading to delays in the approval of products. This particularly affects the IVD industry, where a large number of products have to be recertified. These delays lead to supply bottlenecks and loss of revenue for manufacturers. <\/div><\/div><\/div>
<\/i><\/div>
Transition periods and uncertainties<\/div><\/div>
<\/div>
Although there are transitional periods, many manufacturers are having difficulties adapting their products to the new regulations in time. The uncertainties in the approval process lead to uncertainty on the market and could hamper innovation. With the IVDR in particular, there are concerns that not enough time has been given to certify the numerous products affected. <\/div><\/div><\/div>
<\/i><\/div>
Burden on the healthcare system<\/div><\/div>
<\/div>
The higher costs and longer approval processes can affect the prices of medical devices and diagnostics, which ultimately places a burden on the healthcare system. Smaller manufacturers could be squeezed out of the market due to the higher regulatory hurdles, reducing the variety of products and possibly leading to less competition and higher prices. <\/div><\/div><\/div>
<\/i><\/div>
Focus on existing products<\/div><\/div>
<\/div>
\n
The stricter requirements for clinical evaluation mean that many products already on the market have to be reviewed more extensively. As a result, resources are being used to re-certify existing products instead of focusing on innovation and new developments. <\/div>\n

 <\/p>\n<\/div><\/div><\/div>

<\/div><\/div>

Special challenges for SMEs<\/h2><\/h2><\/div>

For SMEs and start-ups, the new MDR and IVDR regulations are a particular challenge. The higher costs, lack of internal resources, delays in market launch and intense competition with larger companies are putting these companies under severe pressure and many smaller organizations are faced with the decision of whether to continue investing in new products or withdraw from certain market segments. The additional bureaucratic and financial burdens could lead to a weakening of the innovative strength of these companies, which could affect the dynamics of the medical technology and diagnostics industry in the long term. <\/p>\n<\/div><\/div><\/div>

What could be the solutions?<\/h2><\/h2><\/div>